Dose selection for prostate cancer patients based on dose comparison and dose response studies

Area of Science:

• Radiation Oncology
• Medical Physics
• Urologic Oncology

Background:

• Three-dimensional conformal radiation therapy (3D CRT) is a standard treatment for prostate cancer.
• Determining the optimal radiation dose is crucial for maximizing treatment efficacy and minimizing toxicity.
• Patient-specific factors, including prostate-specific antigen (PSA) levels and tumor characteristics, influence treatment response.

Purpose of the Study:

• To define the appropriate radiation dose for individual prostate cancer patients undergoing 3D CRT.
• To investigate the relationship between radiation dose and biochemical no evidence of disease (bNED) outcomes.
• To identify patient subgroups that benefit most from dose escalation.

Main Methods:

• Analysis of 618 patients treated with 3D CRT between 1989 and 1997, with a median follow-up of 53 months.
• Patients were stratified by PSA levels (<10, 10-19.9, 20+ ng/ml) and clinical characteristics (favorable vs. unfavorable).
• Dose comparisons and dose-response functions were generated to assess 5-year bNED rates across subgroups and specific dose levels (e.g., 73 Gy vs. 78 Gy).

Main Results:

• Significant improvements in 5-year bNED rates (22-40%) were observed with higher doses in three of six patient subgroups.
• Dose-response analysis showed significant differences when comparing 73 Gy and 78 Gy in four subgroups (15-43% improvement).
• No significant dose-response difference was found for favorable <10 ng/ml PSA or unfavorable >=20 ng/ml PSA subgroups.

Conclusions:

• Radiation dose response in prostate cancer varies significantly based on patient subgroupings.
• Personalized dose selection for 3D CRT can optimize 5-year cure rates, potentially exceeding those of other treatments.
• National guidelines should be updated to support the safe delivery of higher doses (75-80 Gy) with 3D CRT.